Ticker League

Total Equity for SELLAS Life Sciences Group (SLS)

As of · Reported

Metric

Latest period

$107.41M

YoY change

+648.8%

5Y CAGR

+20.4%

Peak year (2025)

$70.87M

Total Equity history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025

Latest: $70.87M

Total Equity growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025

Latest: +648.8%

Total Equity history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025

  • 2025$70.87M+648.8%
  • 2024$9.46M-218.7%
  • 2023−$7.98M-264.4%
  • 2022$4.85M-76.2%
  • 2021$20.35M-27.2%
  • 2020$27.96M+358.9%
  • 2019$6.09M+16.2%
  • 2018$5.25M+153.4%
  • 2017$2.07M-92.8%
  • 2016$28.66M+112.1%
  • 2015$13.51M-63.5%
  • 2014$37.06M+529.6%
  • 2013$5.89M-78.8%
  • 2012$27.76M+174.5%
  • 2011$10.11M+316.1%
  • 2010$2.43M+227.9%
  • 2009$741.00K-91.7%
  • 2008$8.97M-17.1%
  • 2007$10.82M+541050.0%
  • 2006$2.00K—

Total Equity values are taken from SELLAS Life Sciences Group's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Total Equity at SELLAS Life Sciences Group (SLS)

According to SELLAS Life Sciences Group's latest reported financial statements, the company's latest reported total equity is $107.41M. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, SELLAS Life Sciences Group (SLS) reported total equity of $70.87M – surged 648.8% year-over-year.

Looking at the 2020–2025 (5 years) stretch, SELLAS Life Sciences Group total equity compounded at +20.4% per year, sustaining 2 straight years of year-over-year growth.

2025 marks the peak total equity at $70.87M, with the historical low of −$7.98M recorded in 2023.

SELLAS Life Sciences Group Total Equity by Year

SELLAS Life Sciences Group Total Equity 2025: $70.87M

In 2025, SELLAS Life Sciences Group reported total equity of $70.87M, surged 648.8% from 2024. This figure represents the highest annual value in the available history.

SELLAS Life Sciences Group Total Equity 2024: $9.46M

SELLAS Life Sciences Group total equity in 2024 was $9.46M, plunged 218.7% below 2023.

SELLAS Life Sciences Group Total Equity 2023: −$7.98M

2023's total equity for SELLAS Life Sciences Group came in at −$7.98M, plunged 264.4% below 2022. This figure represents the lowest annual value in the available history.

SELLAS Life Sciences Group Total Equity 2022: $4.85M

SELLAS Life Sciences Group posted total equity of $4.85M in 2022, plunged 76.2% below 2021.

SELLAS Life Sciences Group Total Equity 2021: $20.35M

SELLAS Life Sciences Group total equity in 2021 was $20.35M.

See more financial history for SELLAS Life Sciences Group (SLS).

Sector peers by Total Equity

Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest total equity

Frequently asked questions

SELLAS Life Sciences Group (SLS) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview
Capital Return

No dividends paid by this company.